Big data identifies lipids as signatures of health and disease

Biology is swaddled in lipids: fats, oils, and even waxes envelop cells and their organelles, mediate the flow of vast biological information networks, protect fragile tissues, and store essential energy across multiple organisms. But despite their importance, lipids have traditionally been among the hardest biomolecules to study because of the diversity of their molecular structures, which are not determined by the well-defined building blocks and simple rules that govern DNA, RNA, and proteins. And this diversity means that, unlike building and analyzing genome and transcriptome databases, lipids require more customized analytic procedures.

Because of this, it is very difficult to study either the physiological function of a vast majority of lipid species or the way they are so precisely regulated in cells. But while lipidomics technologies are progressing, translating their findings into medical applications and introducing them into clinical laboratories is still a considerable challenge.

This is the challenge that the team of Johan Auwerx at EPFL, in collaboration with Dave Pagliarini's group at the University of Wisconsin-Madison took on by measuring almost 150 lipid species in the blood and liver of mice. They also followed this up by identifying the genetic regulators of each lipid species as well as their physiological functions.

The researchers used systems genetics approaches to combine the lipidomics data with other "omics" datasets (phenomics, proteomics, transcriptomics) from this population of mice (so-called BXD). The approach identified plasma and blood lipid species from different lipid classes as signatures of healthy or unhealthy metabolic states.

For example, the scientists demonstrated seven plasma triglyceride species as signatures of healthy or fatty liver and non-alcoholic fatty liver disease (NAFLD). Their observation was validated in an independent dietary and therapeutic model of NAFLD in mice and in plasma from patients with NAFLD.

"This finding fuels optimism that lipid species could serve as signatures or biomarkers that will replace the invasive tissue biopsies currently used to diagnose diseases such as NAFLD - simply by measuring specific lipid species in the blood," says Johan Auwerx.

In a companion paper published at the same time, the authors identify as signatures of healthy or fatty liver a subset of the cardiolipin lipids, which are the essential phospholipids in the inner membrane of mitochondria.

In both papers, the researchers pinpoint several genetic locations that may regulate the production of lipid species. By comparing the genetic data from the BXD mouse population to data from so-called genome-wide association studies of lipid-related disorders in humans, they were able to identify common genes between mice and humans that regulate lipids.

"Analyzing lipids and finding their physiological role may never be as straightforward as studying nucleic acids or proteins," says Auwerx. "But these companion studies provide a foundation for understanding the genetic regulation and physiological significance of lipid species, while yet again demonstrating the potential of Big Data mining to address biological and clinical questions."

Pooja Jha, Molly T McDevitt, Emina Halilbasic, Evan G Williams, Pedro M Quiros, Karim Gariani, Maroun B Sleiman, Rahul Gupta, Arne Ulbrich, Adam Jochem, Joshua J Coon, Michael Trauner, David J Pagliarini, Johan Auwerx.
Genetic regulation of plasma lipid species and their association with metabolic phenotypes.
Cell Systems 13 June 2018. doi: 10.1016/j.cels.2018.05.009.

Pooja Jha, Molly T McDevitt, Rahul Gupta, Pedro M Quiros, Evan G Williams, Karim Gariani, Maroun B Sleiman, Leo Diserens, Adam Jochem, Arne Ulbrich, Joshua J Coon, Johan Auwerx, David J Pagliarini.
Systems analyses reveal physiological roles and genetic regulators of liver lipid species.
Cell Systems 13 June 2018. doi: 10.1016/j.cels.2018.05.016.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...